OWCP (OWC Pharmaceutical Research) Total Debt per Share: $0.00 (As of Sep. 2019)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is OWC Pharmaceutical Research Total Debt per Share?

OWC Pharmaceutical Research OWCP -90.00% Total Debt per Share is $0.00 as of Sep. 2019.

$0.00 (As of Sep. 2019)

Total Debt per Share is calculated as total debt divided by Shares Outstanding (EOP). Total debt is calculated as Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. OWC Pharmaceutical Research's Total Debt Per Share for the quarter that ended in Sep. 2019 was $0.00.

OWC Pharmaceutical Research Total Debt per Share Historical Data

* Premium members only.

The historical data trend for OWC Pharmaceutical Research's Total Debt per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OWC Pharmaceutical Research Total Debt per Share Chart

OWC Pharmaceutical Research Annual Data
Trend Dec08 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Total Debt per Share
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

OWC Pharmaceutical Research Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Total Debt per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

OWC Pharmaceutical Research Total Debt per Share Calculation

OWC Pharmaceutical Research's Total Debt Per Share for the fiscal year that ended in Dec. 2018 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(0.00+0.00)/150.21
=0.00

OWC Pharmaceutical Research's Total Debt Per Share for the quarter that ended in Sep. 2019 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(0.02+0.03)/244.48
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Debt per Share →
What does a Total Debt per Share of $0.00 mean?
OWC Pharmaceutical Research (OWCP) has a Total Debt per Share of $0.00 as of Sep. 2019. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on OWC Pharmaceutical Research and its competitors.
Is OWC Pharmaceutical Research's Total Debt per Share too high?
OWC Pharmaceutical Research's current Total Debt per Share is $0.00.
How does OWC Pharmaceutical Research's Total Debt per Share compare to PARNF and CANB?
OWC Pharmaceutical Research's Total Debt per Share of $0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Debt per Share for a Drug Manufacturers company?
A good Total Debt per Share depends on the Drug Manufacturers industry context. However, Total Debt per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Debt per Share mean?
A high Total Debt per Share can signal that a stock is expensive relative to its fundamentals. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on OWC Pharmaceutical Research and its competitors. OWC Pharmaceutical Research's current Total Debt per Share is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OWC Pharmaceutical Research stock overvalued right now?
OWC Pharmaceutical Research (OWCP) has a current Total Debt per Share of $0.00. The current Total Debt per Share is $0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Debt per Share calculated?
Total Debt per Share is calculated from a company's financial statements. For OWC Pharmaceutical Research (OWCP), the current Total Debt per Share is $0.00 as of Sep. 2019. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

OWC Pharmaceutical Research Business Description

Address 2 Ben Gurion Street, Ramat Gan, ISR, 4514760
OWC Pharmaceutical Research Corp is a medical cannabis research and development company. The firm through its subsidiary researches and develops cannabis-based products and treatments specifically designed for multiple myeloma, psoriasis, fibromyalgia, post-traumatic stress disorder (PTSD), migraine, sexual function and skin disorders. It also provides consulting services to governmental and private entities to assist them with developing and implementing tailor-made medical cannabis program.